Karyopharm drug tested in ‘industry-first’ approach to brain cancer

07:16 EDT 12 Jul 2019 | pharmaphorum

Karyopharm’s new drug Xpovio is to be tested in a new type of clinical trial designed to rapidly select individualised treatment combinations for brain cancer. The unusual phase 0/2 design starts with a preclinical phase in which Xpovio (selinexor)...

Original Article: Karyopharm drug tested in ‘industry-first’ approach to brain cancer


More From BioPortfolio on "Karyopharm drug tested in ‘industry-first’ approach to brain cancer"

Quick Search

Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...